French Diatos Elected Among the 15 Emerging Biotech Companies 2004 for Its Innovative Technologies and International Developmen

29-Jul-2004

Paris. Diatos S.A., a privately held biopharmaceutical company, announced today that the company has been elected as an awardee of FierceBiotech's annual "The Fierce 15," a list of the top emerging biotech companies of 2004. Diatos is developing a clinical pipeline of anti-cancer products.

FierceBiotech Editor-in-chief John D. Carroll lauded Diatos's research efforts in 2004, saying "Diatos has pioneered two technologies for cancer and other life-threatening diseases, and is preparing to advance its innovative therapeutic products into clinical trials."

"FierceBiotech is well-known for its coverage of biotech trends and successful business strategies," said Dr. John Tchelingerian, President and Chief Executive Officer of Diatos. "Being selected as a member of The Fierce 15 is an honor that recognizes Diatos's emerging international presence in the biotech industry."

The Fierce 15 celebrates the spirit of being "fierce" - daring to be innovative and aggressive, even in an industry with a long time-to-market. The list of Fierce 15 companies is available in today's issue of FierceBiotech and on their web site at www.fiercebiotech.com.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances